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Abstract 23 
Oxidative phosphorylation system (OXPHOS) deficiencies are rare diseases but constitute the 24 
most frequent inborn errors of metabolism.  We analyzed the autophagy route in 11 skin 25 
fibroblast cultures derived from patients with well characterized and distinct OXPHOS defects. 26 
Mitochondrial membrane potential determination revealed a tendency to decrease in 5 27 
patients’ cells but reached statistical significance only in 2 of them. The remaining cells showed 28 
either no change or a slight increase in this parameter. Colocalization analysis of mitochondria 29 
and autophagosomes failed to show evidence of increased selective elimination of 30 
mitochondria but revealed more intense autophagosome staining in patients’ fibroblasts 31 
compared with controls. Despite the absence of increased mitophagy, Parkin recruitment to 32 
mitochondria was detected in both control and patients’ cells and was slightly higher in cells 33 
harboring complex I defects. Western blot analysis of the autophagosome marker LC3B, 34 
confirmed significantly higher levels of the protein bound to autophagosomes, LC3B-II, in 35 
patients’ cells, suggesting an increased bulk autophagy in OXPHOS defective fibroblasts. 36 
Inhibition of lysosomal proteases caused significant accumulation of LC3B-II in control cells, 37 
whereas in patients’ cells this phenomenon was less pronounced. Electron microscopy studies 38 
showed higher content of late autophagic vacuoles and lysosomes in OXPHOS defective cells, 39 
accompanied by higher levels of the lysosomal marker LAMP-1. Our findings suggest that in 40 
OXPHOS deficient fibroblasts autophagic flux could be partially hampered leading to 41 
accumulation of autophagic vacuoles and lysosomes.  42 
 43 
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1. INTRODUCTION 47 
Autophagy is a route of degradation of cellular components that can be induced by different 48 
stimuli. Several forms of autophagy exist and among them, macroautophagy (hereafter 49 
autophagy), involves the formation of double-membrane vesicles called autophagosomes that 50 
enwrap and sequester the cellular component to be eliminated (for a review see [1]). After 51 
cargo sequestration, autophagosomes fuse with lysosomes that will digest the sequestered 52 
material, allowing recycling of some of its components or supporting energy production. This 53 
type of autophagy is, so far, the only known route to clear large structures and entire 54 
organelles, such as mitochondria. Although this pathway was mainly considered as a bulk 55 
sequestration process, selective autophagy to degrade excessive or damaged organelles was 56 
initially described by Kissova et al [2], and to emphasize the non-random elimination of 57 
defective mitochondria, the term mitophagy was proposed [3]. In recent years mitophagy has 58 
been related to dissipation of mitochondrial membrane potential (ΔΨ), which could trigger the 59 
elimination of the organelle [2, 4-8]. Since the beginning of this century it has been highlighted 60 
that mitochondria are dynamic organelles that continuously fuse and divide. These processes, 61 
generally termed mitochondrial dynamics, fine-tune fundamental cellular pathways, and 62 
alterations in them can constitute both cause and effect of disease [9]. It has been proposed 63 
that after fission, if the resulting mitochondria are dysfunctional and not able to repolarize, 64 
fusion is impaired and mitochondria are kept in an isolated state in which they are tagged and 65 
recruited for digestion and elimination by autophagy [2, 4-8, 10, 11]. Thus, autophagy and 66 
mitochondrial dynamics would cooperate to target dysfunctional mitochondria for elimination 67 
and would help maintaining the bio-energetic efficiency of the cell. Nevertheless, the selective 68 
inhibition of mitochondrial fusion by mitochondrial dysfunction has been only demonstrated in 69 
yeast [12], and how mitochondrial dynamics could aid in the elimination of dysfunctional 70 
mitochondria is still a matter of research. 71 
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Primary mitochondrial diseases (MD) caused by dysfunction of the oxidative phosphorylation 72 
system (OXPHOS) are the most frequent inborn errors of metabolism. Cells from MD patients 73 
show decreased ΔΨ due to diminished electron flow through the respiratory chain [13-18], 74 
suggesting that the selective elimination of defective mitochondria in cells from patients with 75 
MD could be increased. Nevertheless, this possibility has not been studied in depth. In fact, 76 
only three reports exist describing increased mitophagy in cells from patients with primary 77 
coenzyme Q deficiency and patients with coenzyme Q deficiency associated with mutations in 78 
mitochondrial DNA (mtDNA) [19-21]. In tissues from animal models of MD evidence of 79 
increased autophagy has been reported. For instance, in a mouse model of mitochondrial 80 
myopathy due to mutation in the mitochondrial helicase Twinkle, evidence of an increased 81 
autophagic starvation-like response, involving mitophagy in skeletal muscle, has been 82 
described [22, 23]. In addition, in a murine model of dominant optic atrophy, an increased 83 
amount of autophagosomes was found in retinal ganglion cells [24]. These evidences support 84 
the hypothesis that mitochondrial deficiency could induce a stress signal leading to increased 85 
autophagy as compensatory response, either to obtain energy or to eliminate damaged 86 
mitochondria that could induce further cellular dysfunction. 87 
The goal of our study was to evaluate the autophagic response in primary skin fibroblasts 88 
derived from 11 MD patients, with well characterized and distinct mutations in nuclear and 89 
mitochondrial OXPHOS genes, and to further analyze the role of mitophagy in the 90 
pathophysiology of MD. These cells were divided in 4 differentiated groups attending to the 91 
respiratory chain deficiency they presented: (i) fibroblasts with isolated complex I deficiency 92 
due to mutations in NDUFV1 and NDUFA1 (n=3); (ii) fibroblasts with complex III deficiency 93 
harboring mutations in the complex III assembly factor BCS1L (n=5); (iii) fibroblasts with 94 
mutations in the complex IV assembly factor SURF1 and in the mitochondrial encoded complex 95 
IV gene COX2 (n=2); and (iv) one cell line with decreased mitochondrial content due to 96 
mutations in SUCLG1.  97 
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2. MATERIALS AND METHODS 98 
2.1 Cell culture and treatments 99 
Skin fibroblasts from MD patients were cultured in DMEM with high glucose (4.5 g/L) 100 
supplemented with 10% fetal calf serum, penicillin 50 IU/mL and streptomycin 50 IU/mL.  Cells 101 
were routinely checked to be free of mycoplasms.  102 
Respiratory chain (RC) deficiency detected in each cell line and the patients’ (P) main genetic 103 
data are shown in Table 1. Cell lines from P1-P3 showed isolated complex I deficiency due to 104 
mutations in either the complex I catalytic subunit NDUFV1 or in the structural subunit 105 
NDUFA1 [25, 26]. Cell lines from P4-P6 and P8 showed either isolated or combined complex III 106 
deficiency due to mutations in the complex III assembly factor BCS1L[27-30], whereas P7 did 107 
not show significant alteration of RC activities in fibroblasts but decreased complex III in 108 
skeletal muscle [30]. P9 and P10 showed complex IV deficiency due to mutations in the 109 
assembly factor SURF1 and in the structural subunit COX2 respectively, the latter showing 60% 110 
heteroplasmy [31]. The combined RC deficiency found in P11 was due to decreased levels of 111 
mitochondrial DNA caused by mutations in SUCLG1 [32]. 112 
We have studied fibroblasts from skin biopsies obtained for research purposes after written 113 
informed consent. The research was approved by the Ethics Committee at Hospital 12 de 114 
Octubre and is in accordance with the Helsinki Declaration. 115 
To analyze autophagy-dependent degradation of LC3, cells were maintained in culture medium 116 
with freshly prepared E64d and pepstatin A (Sigma) at 10 µg/mL in DMSO for 4 h according to 117 
Kimura et al [33]. Cells were washed with ice-cold PBS, scraped and centrifuged at 800 x g for 5 118 
min at 4º C. Cells were subsequently resuspended in lysis buffer and western blot analysis was 119 
performed to detect LC3B as described below.  120 
 121 
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2.2 Western blot analysis in cell lysates 122 
Fibroblasts were lysated in 5 mM Tris pH 8.0, 20 mM EDTA, 0.5 % Triton X-100, protease and 123 
phosphatase inhibitor cocktail (Roche), centrifuged at 11.000 x g, and supernatant was 124 
collected. Protein content of the supernatants (cell lysates) was determined [34] . Samples of 125 
cell lysates (5-10 µg) were used to perform semi-quantitative analysis, by Western Blot, of the 126 
levels of: LC3B (anti-LC3B Sigma), LAMP-1 (anti-LAMP-1 G1/139/5, DHSB), and pyruvate 127 
dehydrogenase E1 alpha (PDH-E1-α), complex II 70 kDa subunit (SDHA), and Complex V α 128 
subunit (CVα), all from Mitosciences. Immunodetection of primary antibodies was carried out 129 
with peroxidase-conjugated secondary antibodies (GE Healthcare). The signal was detected 130 
with Enzyme Chemiluminiscence (Novex® ECL HRP Chemiluminiscent Substrate Reagent Kit, 131 
Life Technologies S.A.). Band densities were evaluated by densitometric scanning (Image J 132 
software). β actin or α tubulin were immunodetected with mouse anti-β actin and anti-α 133 
tubulin (both from Sigma) and used as loading control.   134 
 135 
2.3 ATP content measurements 136 
Cellular ATP was extracted from cells in boiling 100 mM Tris, 4 mM EDTA pH 7.75, and assayed 137 
by bioluminescence using a luciferin-luciferase system (Roche) according to manufacturer’s 138 
instructions. ATP concentration was corrected by cell number and expressed as percentage of 139 
control cells’ ATP content. 140 
 141 
2.4 Confocal microscopy in living cells 142 
Mitochondrial membrane potential (ΔΨ) was analyzed by confocal microscopy in living cells as 143 
described by Davidson et al[35]. In brief, plasma membrane was depolarized by the addition of 144 
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potassium to 50 mM and cells were loaded with 30 nM tetramethylrodhamine methyl ester 145 
(TMRM) for 60 min in a CO2 incubator. Image collection was carried out in cells maintained at 146 
37º C with a 40x lens using 543 nm laser set at 1.5% intensity. TMRM intensity per cell was 147 
analyzed with Image J software and corrected by citrate synthase activity, a classical marker of 148 
cellular mitochondrial content that was determined in cultured cells as described elsewhere 149 
[36]. 150 
To evaluate lysosomal content living fibroblasts were loaded with 50nM Lysotracker™ DND-26 151 
(Molecular Probes) for 90 min in the dark in a CO2 incubator. Image collection was carried out 152 
with a 40x lens using the 488 nm excitation laser line set at 2% intensity, with cells maintained 153 
at 37º C. Cells were imaged randomly with 1 µm slices and 1024x1024 pixel resolution.  154 
Lysotracker intensity per cell was analyzed with the Image J software. No enhancement of the 155 
original images was done. 156 
 157 
2.5 Immunofluorescence  158 
Immunofluorescence was performed on sub-confluent paraformaldehyde-fixed cells. Mouse 159 
monoclonal anti-C Vα (MitoSciences), and rabbit anti-LC3B or anti-Parkin (Sigma) were used as 160 
primary antibodies. Texas Red-conjugated anti-mouse (MitoSciences) and Alexa-488-161 
conjugated anti rabbit were used as secondary antibodies. Coverslips were mounted in 162 
ProLong Gold© antifade reagent (Molecular Probes) on glass slides. Cells were viewed with a 163 
Zeiss LSM 510 Meta confocal microscope with a 63x planapochromat oil immersion objective 164 
(NA: 1.42), sequential scanning of green and red channels were performed to avoid bleed-165 
through effect. Cells were imaged randomly with 0.5-0.7 µm slices and 1024x1024 pixel 166 
resolution. For colocalization analysis we used the plugin “Colocalization” and the plugin 167 
“JaCOP” to determine Manders’ coefficients, both from Image J. No enhancement of the 168 
original images was done. 169 
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2.6 Electron microscopy (EM) 170 
Adherent non confluent cells were fixed in 2% glutaraldehyde and 4% paraformaldehyde in 0.1 171 
M sodium phosphate buffer (pH 7.4) for 90 min at room temperature, washed with PBS and  172 
then post-fixed in 1% OsO4 for 1 h at 4º C. After dehydration in graded series of ethanol, the 173 
cells were embedded in Epon 812 (Fluka) and polymerized at 60º C for 2 days. Ultrathin 174 
sections (90 nm) were analyzed in a JEOL JEM1010 transmission electron microscope equipped 175 
with a 4Kx4K TemCam-F416 digital camera (TVIPS, Gauting, Germany). Identification of 176 
autophagosomes, late autophagic vesicles, lysosomes and estereological counting was 177 
performed as described previously [37-40]. 178 
 179 
2.7 Data Analysis 180 
All experiments, except electron microscopy, were performed at least in triplicate. Data are 181 
presented as mean ± standard deviation (SD). Six different control primary skin fibroblasts 182 
were used in the present study, and 4 to 6 different controls were evaluated for the 183 
determination of each parameter. Due to the poor growth rate of patients’ cells not all the 184 
determinations could be performed in all patients’ cell lines. Statistical analysis was performed 185 
with the SPSS software (SPSS, Chicago, IL) and statistical significance was set at P <0.05. When 186 
Kruskall-Wallis test was applied, to minimize the risk of statistical error type 1, after post hoc 187 
analysis we only performed comparison between control and patients’ groups. Densitometry 188 
of western blots and confocal images analysis were performed with Image J (Rasband, W.S., 189 
ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 190 
1997-2012). To perform the analysis of lysosomal flux, LC3B-II/actin ratio in non-treated cells 191 
were set as basal values of the autophagic marker for each cell line, and increases in LC3B-192 
II/actin in protease inhibitors-treated cells were expressed as a percentage of its basal values.  193 
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3. RESULTS 194 
3.1 Mitochondrial dysfunction causes mild alterations in mitochondrial membrane potential 195 
and decreased ATP content 196 
To assess if ΔΨ is lower in the MD cells and mitophagy could be induced, we determined this 197 
parameter by confocal microscopy as mean TMRM fluorescence per cell in eleven MD primary 198 
skin fibroblasts showing: complex I deficiency due to mutations in NDUFV1 and NDUFA1 (P1-199 
P3), complex III deficiency caused by mutations in the assembly factor of this complex, BCS1L 200 
(P4-P8), two cell types with mutations in the complex IV assembly factor SURF1 and the 201 
mitochondrial encoded complex IV gene COX2 (P9, P10), and one cell culture with decreased 202 
mitochondrial content due to mutations in SUCLG1 (P11) (Figure 1A). Statistical analysis 203 
demonstrated a significant cell line effect (Kruskal Wallis test P = 0.047). Mean ΔΨ was 204 
decreased in P1, P3 and P8-P11, and post-hoc analysis revealed significantly lower levels  in P9 205 
and P10, both affected by complex IV deficiencies. On the contrary, a slight hyperpolarization 206 
was detected in P4 and P5, both affected by a complex III enzymatic defect.   207 
We have previously shown that in the CI-deficient cells analyzed in the present investigation 208 
ATP content is significantly lower compared to control cells [26]. To assess the bionergetic 209 
state in the remaining MD cells we also determined the ATP content, finding, in agreement, 210 
significantly lower levels of this parameter in complex III-deficient  cells and P11 (Figure 211 
1B,Mann-Whitney test P = 0.01 for patients vs. controls).  212 
 213 
3.2 Mitochondrial dysfunction induces increased autophagic response but does not alter  214 
mitophagy 215 
Mitophagy was assessed in MD cell lines, by confocal microscopy analysis of mitochondria 216 
labeled with an antibody against complex V α subunit (CVα) , and autophagosomes labeled 217 
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with an antibody against the classical marker of these structures, LC3B [41]. The 218 
autophagosome staining pattern revealed a more intense signal in MD cells in comparison with 219 
control cells, regardless of their mean mitochondrial membrane potential, displaying LC3 220 
puncta and also patched signal (Figure 2). Nevertheless, colocalizations between fragmented 221 
mitochondria and autophagosomes were very scarce, even in cells with high amounts of 222 
fragmented mitochondria, i.e. from P8. Only in few cases small dotted mitochondria 223 
colocalized with LC3 puncta, and most of the colocalization detected occurred in reticular 224 
mitochondria suggesting that only a small number of fragmented mitochondria were being 225 
selectively eliminated (see Figure 2, P6 inset). Colocalization according to Mander’s 226 
coefficients, was low in both controls and MD cells, although a slight increase in Mander’s 227 
coefficient for the green channel in the patients’ fibroblasts was detected (Mander’s 228 
coefficients for the red channel were 0.128 ± 0.09 for controls’ cells and 0.093 ± 0.08 for MD 229 
cells, and Mander’s coefficients for the green channel were 0.154 ± 0.08 for controls’ cells and 230 
0.234 ± 0.13 for MD cells). Images of control and MD fibroblasts with both channels separately 231 
depicted are shown in Supplemental Figures 1A and 1B, also the quantitative analysis of mean 232 
LC3B fluorescence per cell is shown in Supplemental Figure 1C (Mann-Whitney test P = 0,014 233 
for patients vs. controls). These findings would indicate that bulk autophagy is higher than 234 
normal in MD fibroblasts, but this phenomenon is not due to augmented elimination of 235 
defective mitochondria.  236 
As CVα was used as a mitochondrial marker in our immunofluorescence assays, we tested the 237 
levels of this protein in the MD cells to exclude putative alterations in the mitochondrial 238 
network staining that could bias our findings. Western blot analysis showed that CVα levels 239 
were not decreased by the OXPHOS deficiencies present in our MD cells (Figure 3A). If 240 
increased mitophagy occurred due to OXPHOS deficiency, we could expect lower 241 
mitochondrial content in the MD cells compared with those of healthy controls. Previous data 242 
from our laboratory have shown that the levels of several key mitochondrial proteins (SDHA, 243 
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CORE2, COX2) were not generally lower than normal in fibroblasts P2-P8, suggesting that their 244 
mitochondrial content was neither affected [25, 26, 30]. To further corroborate that 245 
mitochondrial content was not altered in any of the MD cells studied in the present work we 246 
analyzed the levels of key mitochondrial proteins, such as complex II 70 kDa subunit (SDHA) 247 
and the mitochondrial matrix protein pyruvate dehydrogenase E1-alpha (PDH-E1-α) because 248 
these proteins are commonly used as mitochondrial content markers. The levels of these 249 
proteins were not significantly lower in the MD cells compared with the controls (Figure 3B). 250 
Analysis of the densitometry of CVα, SDHA and PDH-E1-α are shown in Supplemental Figure 2. 251 
Levels of SDHA, CVα and PDH-E1-α in 6 different control fibroblasts and 2 MD cells (P1 and P4) 252 
are shown in Figure 3C. These findings suggest that the mitochondrial content is not altered in 253 
any of MD cells analyzed, in agreement with previous research from our group [26]. 254 
We also checked the levels of protein markers for other organelles (peroxisomes, endoplasmic 255 
reticulum and Golgi apparatus), but overall we did not detect lower values in the MD cells 256 
studied (Supplemental Figure 3). These results indicate that increased autophagy in the MD 257 
fibroblasts do not seem to induce the specific elimination of any organelle, i.e., mitochondria, 258 
peroxisomes, endoplasmic reticulum, or Golgi apparatus.  259 
To analyze if the absence of mitophagy in MD-derived fibroblasts could be due to defective 260 
recruitment of dysfunctional mitochondria to autophagy, we studied the molecular labeling of 261 
mitochondria with Parkin (Figure 4). The analysis of double-stained cells with anti-Parkin and 262 
anti-CVα antibodies showed punctated Parkin signal. Colocalization between Parkin and 263 
mitochondria was evident, in fragmented and isolated mitochondria, and also in mitochondria 264 
of tubular shape in both control and MD fibroblasts.  Images of control and MD fibroblasts 265 
with both channels separately depicted are shown in Supplemental Figure 4A and 4B. 266 
Interestingly, fibroblasts affected by complex I deficiency (P1-P3) showed more intense Parkin 267 
staining in tubular mitochondrial network than control cells. Mander’s coefficient for the red 268 
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channel were 0.537 ± 0.2 (control fibroblasts), 0.642 ± 0.014 (P1), 0.768 ± 0.06 (P2) and 0.880 ± 269 
0.01 (P3). Mander’s coefficient for the green channel were 0.280 ± 0.07 (control fibroblasts); 270 
0.272 ± 0.05 (P1); 0.233 ± 0.06 (P2) and 0.151 ± 0.02 (P3).  271 
Although we could not find increased mitophagy in patients’ fibroblasts, increased LC3B 272 
staining in MD cells was shown by immunofluorescence. Therefore, we determined the basal 273 
levels of autophagy by western blot analysis of LC3B in total cell lysates. Higher levels of LC3B-274 
II, the LC3 form associated with autophagosomes, was found in the patients’ cell lines (Mann-275 
Whitney test P = 0.013 for patients vs. controls) (Figure 5A and Figure 5B). These results 276 
indicate higher autophagosome content in the cells from MD patients. Normal range of LC3B in 277 
six different control cell lines is shown in Figure 5C with two MD cells (P1 and P4) for better 278 
comparison between patients and controls. 279 
 280 
3.3 Autophagosome clearance is not altered in the autophagic response in mitochondrial 281 
diseases but autophagic vacuoles are accumulated in fibroblasts derived from MD patients 282 
To analyze if the increased LC3B-II detected in the patients’ cells lysates was due to a failure of 283 
lysosomal activity we treated the cells with protease inhibitors E64D and pepstatin A (Figure 284 
6). Control fibroblasts treated with the protease inhibitors showed higher (+150%) amounts of 285 
LCBII  in comparison with vehicle-treated cells, as expected for normal lysosomal-dependent 286 
autophagosome clearance. In most of the MD cell lines we could detect milder increases in the 287 
mean LC3B-II/actin ratio, but P1, P2 and P11 showed increases in mean LC3B-II/actin ratio 288 
similar to those found in controls. Patients cell lines pooled showed 138 % higher levels 289 
compared with controls. The statistical analysis of the autophagosome clearance did not show 290 
statistical significance between the behavior of MD and control cell lines (Mann-Whitney test P 291 
= 0.315 for patients vs. controls).  292 
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We also studied the colocalization between LC3B and mitochondria by immunofluorescence in 293 
bafilomycin A1-treated cells to analyze if under conditions of blocked lysosomal flux we could 294 
detect higher levels of mitophagy in MD cells compared with controls. After bafilomycin 295 
treatment we did not detect any change in the colocalization between mitochondria and 296 
autophagosomes in controls (Mander’s coefficients are shown in Supplemental Table 1, and 297 
representative images of control and P1-trated cells are shown in Supplemental Figure 5). In 298 
MD cells after bafilomycin A1 treatment Mander’s coefficient for the red channel was slightly 299 
higher but remained very low and was similar to that in bafilomycin-treated controls. These 300 
results indicate that there is low colocalization between mitochondria and autophagosomes, 301 
and rules out the possibility that increased mitophagy in basal conditions in MD cells could be 302 
masked by lysosomal degradation of mitochondria-containing autophagosomes. 303 
Transmission electron microscopy revealed that the most outstanding feature of MD cells in 304 
the criosections was a higher amount of cytosolic vacuoles (Figure 7A), but we could not find 305 
evidences of alterations in the mitochondrial ultrastructure of MD cells (Supplemental Figure 306 
6A). Some of these vacuoles could be considered autophagosomes, and hardly any contained 307 
mitochondria. The most abundant vesicles were multilaminar bodies, vacuoles containing 308 
electrondense material and vacuoles with a mixed appearance between both multilaminar 309 
bodies and electrondense vacuoles (examples of these organelles are shown in Supplemental 310 
Figure 6B). These organelles covered extensive areas in patients’ cells and were often large. 311 
According to the morphology criteria of Eskelinen these vacuoles were considered lysosomes, 312 
late or degradative autophagic vacuoles (AVd) and vacuoles due to the fusion between AVd 313 
and lysosomes, respectively [38-40]. The stereological counting of AVd and AVd fused with 314 
lysosomes revealed increased amounts of these organelles per µm2 in the patients’ cells in 315 
comparison with control fibroblasts (Figure 7B) (Mann-Whitney test P < 0.01 for patients vs. 316 
controls).   317 
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To confirm that the higher amount of AVd in the patients’ cells was accompanied by higher 318 
amounts of lysosomes, we performed a western blot against the lysosomal marker LAMP-1 319 
(Figure 8A). The results obtained showed markedly higher levels of this glycoprotein in all 320 
patients’ cells in comparison to controls (Mann-Whitney test P= 0.016 for patients vs. controls 321 
(Figure 8B). Normal range of LAMP-1 levels in 6 different controls are shown in Figure 8C with 322 
2 MD cells (P1 and P4) for better comparison between patients and controls. 323 
In addition, specific lysosome staining with Lysotracker™ DND-26 in living cells, showed by 324 
confocal microscopy higher lysosomal content in MD fibroblasts (Figure 9) (Mann-Whitney  325 
test P = 0,007 patients vs. controls). These results support that higher than normal amounts of 326 
lysosomes are present in MD patients’ derived fibroblasts.  327 
 328 
mTORC1 activity is not decreased in fibroblasts derived from MD patients 329 
To further analyze the state of the autophagic pathway in MD cells, we determined the 330 
phosphorylation levels of P70S6 kinase at threonine 389, which is a direct target of mTORC1, a 331 
protein complex that negatively regulates autophagy. The results obtained are shown in 332 
Supplemental Figure 7. The ratio of phosphorylated p70 S6 kinase/total p70 S6 kinase tended 333 
to be higher in most patients´ cells in comparison with controls, but the analysis did not reach 334 
statistical significance (Mann-Whitney test P > 0.05 for patients vs. controls). These results 335 
suggest that there is no inhibition of mTORC1 in patients’ fibroblasts. 336 
 337 
 338 
 339 
 340 
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4. DISCUSSION 341 
We have shown that mitophagy is not increased in fibroblasts harboring defects in the 342 
OXPHOS system but autophagosomes, lysosomes and late autophagic vacuoles are 343 
accumulated. This phenomenon could be caused either by an induction of non-selective 344 
autophagy due to a pseudo-starvation response, or to an alteration of the autophagic 345 
degradation pathway due to disturbances in some steps of the lysosomal degradation route 346 
leading to the accumulation of partially degraded cellular materials. 347 
Abolished mitochondrial membrane potential due to protonophore treatment causes the 348 
recruitment of Parkin to mitochondria to mediate their elimination by the autophagic 349 
machinery in order to maintain bio-energetic efficiency in the cell [42]. Decreases in 350 
mitochondrial membrane potential have been previously reported in cells from patients with 351 
OXPHOS disorders suggesting that increased mitophagy could also occur in MD models [14-352 
18]. In our work only 2 cell lines showed lower than normal ΔΨ, and similar results were 353 
described previously by Iuso et al., who found, either no alterations or lower ΔΨ, in fibroblasts 354 
from complex I-deficient patients [13]. Perhaps the fact that the decreases in ΔΨ in our MD 355 
cells were milder than full depolarization could be the cause of the absence of mitophagy. 356 
However, we have previously demonstrated in P1 and P3 that after mitochondrial 357 
depolarization and fragmentation, mitochondrial network fusion, a phenomenon dependent 358 
on ΔΨ recovery, was delayed in comparison with control cells, indicating that OXPHOS 359 
deficiencies cause slower kinetics of ΔΨ recovery [26]. Therefore, determination of ΔΨ in 360 
steady-state conditions cannot always reveal dynamic alterations of ΔΨ occurring in MD cells 361 
that could lead to increased mitophagy. Despite the heterogeneity of the MD cell lines 362 
analyzed in the present work (i.e., with differences in ΔΨ alteration, in the severity of the 363 
respiratory defect, isolated deficiencies in some patients vs. combined defects in others, or 364 
mutations in nuclear DNA vs. mutations in mtDNA), we detected overall higher than normal 365 
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levels of the autophagosomal marker LCB-II in all MD cells, suggesting increased autophagy, as 366 
previously reported in other models of MD (17-22). Therefore, enhancement of 367 
autophagosome content but not increased mitophagy might be a general cellular response to 368 
OXPHOS defect that occurs independently of ΔΨ and of the severity of the OXPHOS defect. 369 
Previous studies in primary cultures of fibroblasts derived from patients with OXPHOS 370 
disorders have described increased mitophagy [19-21]. The discrepancies between these 371 
studies and the present findings could be due to the different consequences at cellular level of 372 
the OXPHOS disorder shown between the cells studied. For instance, in the studies by Sanchez-373 
Alcazar´s group all MD cells showed coenzyme Q deficiency, combined respiratory chain 374 
deficiency, decreased ΔΨ, mitochondrial fragmentation, increased levels of oxidative stress 375 
eventually leading to opening the mitochondrial transition pore, and evidences of autophagy 376 
induction, such as increased Atg5 and Beclin levels[19-21]. In the present investigation none of 377 
the analyzed MD cells showed concurrently those alterations, i.e. none presented with 378 
decreased ΔΨ, increased ROS levels and mitochondrial fragmentation at the same time [26] 379 
[30]. Moreover, in the MD cells analyzed in the present work we failed to detect changes in 380 
Atg5-Atg12, and preliminary data from our laboratory suggest the absence of increased 381 
phosphorylation of ULK1 at Ser555 (data not shown), indicating that the initial steps of the 382 
autophagic cascade are not induced. It is tempting to speculate that several signals of 383 
mitochondrial damage, as strong depolarization and increased mitochondrial ROS production 384 
are needed to induce mitophagy. In this regard, it has been reported that both, loss of 385 
mitochondrial ΔΨ and mTORC1 inhibition, are needed synergistically to induce mitophagy in 386 
cells carrying pathogenic mtDNA mutations [43]. Accordingly, yeast cells treated with the 387 
complex III inhibitor antimycin A, at concentrations to induce mild mitochondrial alterations, 388 
showed increased autophagy but no mitophagy [44]. Further studies are needed to unveil the 389 
different autophagic response found in OXPHOS-deficient cells and the trigger(s) responsible 390 
for such phenomenon. On the other hand, it has been shown that cells can spare their 391 
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mitochondria from degradation even after autophagy induction [45-47]. Mitochondria are key 392 
organelles for cell survival; therefore, despite their OXPHOS defects, cells may keep 393 
mitochondria out of degradation, preventing a futile cycle of biogenesis and elimination of 394 
these vital organelles in a cellular context of lack of energy. 395 
In contrast to previous studies indicating that Parkin labels depolarized mitochondria to initiate 396 
mitophagy, we have shown the absence of Parkin-driven mitophagy even in those cell lines 397 
with diminished ΔΨ. These discrepancies could be due to differences in the models of study 398 
employed, i.e., strong mitochondrial depolarization with protonophores vs. milder 399 
depolarization conditions due to OXPHOS defects, overexpression of Parkin vs. endogenous 400 
levels of the protein, or use of cultured cell lines vs. primary cultures [8, 42, 48-50]. Other 401 
authors using primary mammalian cell cultures, such as cortical neurons, have also failed to 402 
show Parkin-mediated mitophagy, even after CCCP-induced mitochondrial depolarization 403 
despite significant Parkin localization to mitochondria [51]. In primary fibroblasts from 404 
Parkinson´s disease patients harboring PINK1 mutations (a model in which alterations of Parkin 405 
behavior are expected) additional external stress stimuli, such as valinomycin treatment, is 406 
needed to visualize differences in Parkin levels and its traslocation to mitochondria between 407 
control and mutant cells [52]. Moreover, it has been reported that in dopaminergic neurons of  408 
MitoPark mice, dysfunctional mitochondria do not recruit Parkin in vivo, and neither the 409 
clearance of dysfunctional mitochondria nor the neurodegenerative phenotype of the animal 410 
was affected by absence of Parkin [53]. In the present work we found Parkin labeling not only 411 
in small dotted mitochondria (that may be partly depolarized), but also in those expected to 412 
have normal mitochondrial potential showing tubular shape, in both controls’ and patients’ 413 
derived cells. These findings are in agreement with previous data showing that, under basal 414 
conditions, Parkin exists in the cytoplasm and also directly associated with mitochondria [51, 415 
54-57]. Also, in trans-mitochondrial cybrid cells genetic- and chemically-induced loss of ΔΨ 416 
triggered Parkin recruitment to mitochondria without causing mitophagy [43]. Given that 417 
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mitochondrial Parkin localization was slightly higher in some MD patients’ cells without 418 
inducing mitophagy, Parkin could be maybe mediating some additional functions different 419 
from mitochondrial labeling for autophagy. In fact, several Parkin roles related to 420 
mitochondrial function have been reported [55, 56]. For instance, mitochondrial localized 421 
Parkin is able to prevent CCCP-induced mitochondrial depolarization in COS-1 and HeLa cells 422 
[57]. Interestingly Vincow et al. demonstrated that Parkin mediates selective nonmitophagic 423 
turnover of mitochondrial respiratory chain proteins in Drosophila in vivo [58], and it has been 424 
proposed that some respiratory chain complexes, such as complex I, may be especially labile 425 
and would require more frequent turnover than other components [59]. Thus, in complex I-426 
deficient cell lines the increased mitochondrial Parkin recruitment to mitochondria could be 427 
maybe related to a role of this protein in mitochondrial membrane potential maintenance 428 
under bio-energetic stress conditions, or also in the event of increased respiratory chain 429 
component turnover due to altered folding of the mutated subunits, instability or disassembly 430 
of respiratory complexes. Findings obtained in autophagy-defective yeast mutants have shown 431 
that supply of amino-acids via bulk autophagy, but not selective autophagy, is important for 432 
the maintenance of respiratory chain function during starvation [60]. Despite the evolutionary 433 
distance between yeast and mammalian cells, these results could suggest that in MD cells, 434 
which are under bio-energetic stress conditions and probably under proteinaceous stress due 435 
to altered respiratory complexes assembly, autophagy of cytoplasmic material might also be 436 
needed to maintain increased turnover of respiratory chain subunits and complexes. 437 
Although autophagy has received more recent attention as a route to clear dysfunctional 438 
organelles,  it has been known for many years that autophagy is an important survival 439 
mechanism during short-term starvation to degrade non-essential components in order to 440 
obtain nutrients for vital biosynthetic reactions [37]. Several studies have described starvation-441 
like response in mouse models of MD and human muscle from patients harboring m.8344 A>G 442 
mutation [22, 23, 61, 62]. Although MD patients, MD animals or MD cellular models are not 443 
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under starvation conditions, their bio-energetic defect prevents them from obtaining high 444 
enough ATP levels  to maintain normal cellular functions [26, 30]. Low levels of ATP in patients’ 445 
cells could trigger autophagy due to inhibition of mTORC1 by activation of AMPK, but our 446 
preliminary results suggested no inhibition of mTORC1 in the MD cells (supplemental Figure 1).  447 
Perhaps, persistent autophagy induction in our model of disease due to chronic low ATP could 448 
cause reactivation of mTOR as previously reported by Yu et al in rat kidney cells[63] . New 449 
insights in the regulation of the autophagic response in yeast have been recently reported by 450 
Graef and Nunnari, who proposed that mitochondrial function can modulate autophagy 451 
independently of mTOR through PKA, by affecting both ATG gene induction and the 452 
autophagic flux (via assembly of Atg into the pre-autophagosomal structures) [64]. The authors 453 
proposed that mitochondrial dysfunction blocks both autophagy induction and autophagic 454 
flux, and that the response induced may vary depending on the nature and severity of the 455 
mitochondrial defect, i.e., collapse of mitochondrial membrane potential vs. only respiratory 456 
chain defect. If this regulatory mechanism could also be applied to mammalian cells, we would 457 
expect both the inhibition of the autophagic flux and of Atg induction in the MD cells studied in 458 
the present work. This would explain the poor response of the MD cells to lysosomal 459 
inhibitors, while LC3B-II accumulation would result of partially blocked lysosomal flux. 460 
Nevertheless, as the autophagosomal flux was only partially hampered in our MD cells, direct 461 
assessment of mTORC1 activity and an in-depth study of the signaling pathways involved in 462 
autophagy regulation could help unveil the mechanisms of autophagy regulation in our cellular 463 
model of disease.  464 
Decreases in ATP levels can also block the autophagy flux independently of mTORC1 because 465 
ATP is required in the sequestration step as well as to maintain lysosomal function [65-69]. 466 
Taken into account that mTORC1 seemed to be active but the amount of AVd was significantly 467 
increased in our MD cells, we could hypothesize that in fibroblasts harboring OXPHOS defects, 468 
autophagic flux could be partially hampered by the lack of energy. This possibility may explain 469 
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that after lysosomal inhibition LC3B-II was only slightly increased in patients’ fibroblast. Similar 470 
results were found in OXPHOS deficient cells from patients presenting MELAS in which ATP 471 
was decreased and bafilomycin treatment did not rise LC3B-II levels [20]. Consequently, in 472 
OXPHOS deficient cells, abnormalities in the lysosomal degradation may contribute to 473 
autophagosome and AVd accumulation.  474 
In conclusion, in a cellular model of disease, OXPHOS deficiencies result in accumulation of 475 
autophagic vacuoles and lysosomes. This vesicular traffic-jam may interfere with normal 476 
cellular function further contributing to the disease. Future studies analyzing the regulation of 477 
autophagy-related signaling cascades in cellular models of disease, and proving the existence 478 
of similar alterations in target human tissues affected by these diseases, i.e., skeletal muscle, 479 
are needed to gain insights into the disturbances of autophagy and its contribution to human 480 
OXPHOS disorders. 481 
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8. Figure Legends 787 
Figure 1. A) Mitochondrial membrane potential determined by confocal microscopy expressed 788 
as mean TMRM fluorescence per cell normalized by citrate synthase activity in control 789 
fibroblasts (C) and fibroblasts from patients with isolated complex I deficiency  (P1-P3), 790 
complex III deficiency (P4-P8), complex IV deficiency (P9, P10) and decreased mtDNA content 791 
(P11). Data presented are mean ± SD (n=3-8). Four different controls were analyzed. Kruskal 792 
Wallis test: significant cell line effect (P = 0.047). * P < 0.05 significantly different of C.  B) ATP 793 
content in controls (C), and cells showing complex III deficiency (P4-P8) and decreased mtDNA 794 
content (P11).Data are presented as mean ± SD (n=3-5). Four control cell lines were analyzed. 795 
Mann-Whitney test P = 0.01 for patients vs. controls. 796 
Figure 2. Immunofluorescence to detect the autophagosomal marker LC3B (green) and the 797 
mitochondrial marker complex V α subunit (red) in control fibroblasts (C) and fibroblasts from 798 
patients with isolated complex I deficiency  (P1-P3), complex III deficiency (P4-P8), complex IV 799 
deficiency (P9, P10) and decreased mtDNA content (P11). Colocalized pixels are shown in 800 
white. P6 Inset: enlarged area showing colocalization of small fragmented mitochondria and 801 
autophagosomes. Five different controls were analyzed. 63x Plan-Apochromat objetive. 802 
Figure 3. A) Western blot analysis of complex V α subunit (CVα) in control fibroblasts(C) and 803 
fibroblasts from patients with isolated complex I deficiency (P1-P3), complex III deficiency (P4-804 
P8), complex IV deficiency (P9, P10), and decreased mtDNA content (P11). β-actin was used as 805 
loading control.  B) Levels of the key mitochondrial proteins, complex II 70 kDa subunit (SDHA) 806 
and pyruvate dehydrogenase E1-α subunit (PDH-E1-α) in control fibroblasts (C) and fibroblasts 807 
from patients with isolated complex I deficiency (P1-P3), complex III deficiency (P4-P8), 808 
complex IV deficiency (P9, P10), and decreased mtDNA content (P11). α-tubulin was used as 809 
loading control.  C) Representative western blot against SDHA,CVα, PDH-E1-α in six different 810 
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control cell lines (C1-C6) and complex I and complex III-deficient cells (P1, P4) with their 811 
respective loading controls (β-actin for SDHA and CVα, and α-tubulin for PDH-E1-α).  812 
Figure 4. Immunofluorescence to detect Parkin (green) and the mitochondrial marker complex 813 
V α subunit (red) in control fibroblasts (C) and fibroblasts from patients with isolated complex I 814 
deficiency (P1-P3), complex III deficiency (P4-P8), complex IV deficiency (P9, P10), and 815 
decreased mtDNA content (P11).  Colocalized pixels are shown in white. Four different controls 816 
were analyzed. 63x Plan-Apochromat objective. 817 
Figure 5. A) LC3B levels in human fibroblasts from patients with isolated complex I deficiency 818 
(P1-P3), complex III deficiency (P4-P8), complex IV deficiency (P9, P10), and decreased mtDNA 819 
content (P11). β-actin was used as loading control. B) Analysis of the densitometry LC3B-820 
II/actin ratio, data are presented as mean ± SD (n=3-5). Five different controls were analyzed. 821 
Mann-Whitney test P = 0.013 for patients vs. controls. C) Representative western blot against 822 
LC3B in six different controls (C1-C6) and complex I and complex III-deficient cells (P1, P4). β-823 
actin was used as loading control. 824 
Figure 6. Autophagic flux in cells treated with lysosomal protease inhibitors E64D and 825 
Pepstatin A (+), or vehicle treated (-). A) Representative western blot to detect LC3B in control 826 
fibroblasts (C) and fibroblast from MD patients with isolated complex I deficiency (P1-P3), 827 
complex III deficiency (P4-P8), complex IV deficiency (P9, P10), and decreased mtDNA content 828 
(P11). β-actin was used as loading control. Please, note that loading was decreased in patients’ 829 
cells to avoid saturation.  B) Analysis of the densitometry of the LC3B-II/actin ratio, data are 830 
presented as mean ± SD (n=3-5). Four different controls were analyzed. Mann-Whitney test did 831 
not show significant differences for patients vs. controls.  832 
Figure 7. A) Electron microscopy of ultrathin sections of control fibroblasts (C) and fibroblasts 833 
derived from MD patients with isolated complex I deficiency (P1-P3), complex III deficiency 834 
(P5, P6, P8), complex IV deficiency (P9), and decreased mtDNA content (P11). Examples of late 835 
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or degradative autophagic vacuoles (AVd) are depicted by arrowheads. Images shown are tiling 836 
of 2x3 or 3x3, 8K individual images. B) Stereological counting of AVd expressed as AVd/µ2, data 837 
are presented as mean ± SD. Four different controls were analyzed. Mann-Whitney test P < 838 
0.01 for patients vs. controls.  839 
Figure 8. A) Lysosomal protein LAMP-1 levels in control fibroblasts (C) and fibroblasts from 840 
patients with isolated complex I deficiency (P1-P3), complex III deficiency (P4-P8), complex IV 841 
deficiency (P9, P10), and decreased mtDNA content (P11). β-actin was used as loading control. 842 
B) Analysis of the densitometry LAMP-1/actin ratio, data are presented as mean ± SD (n=3-5). 843 
Four different controls were analyzed.  Mann-Whitney test P = 0.016 for patients vs controls. 844 
C) Representative western blot against LAMP-1 in six different control cell lines (C1-C6) and 845 
complex I and complex III-deficient cells (P1, P4). β-actin was used as loading control. 846 
Figure 9. A) Lysosomal content in living cells stained with Lysotracker® DND-26: control 847 
fibroblasts (C), fibroblasts from patients with isolated complex I deficiency (P1,P2), complex III 848 
deficiency (P4-P8), complex IV deficiency (P9), and decreased mtDNA content (P11). Cells were 849 
viewed with a Zeiss LSM 510 Meta confocal microscope with a 40x Plan-Neofluar objective. B) 850 
Quantitative analysis of Lysotracker® DND-26 staining intensity in control (C) and MD cells (P1-851 
P11). Four different controls were analyzed. Mann-Whitney test P=0.007 for patients vs. 852 
controls.  853 
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